See ratings and reviews when you sign up for an account.

A Study of the Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Center Reference Endotoxin in Normal Volunteers

This study is currently Recruiting

October 2011 By University of North Carolina, Chapel Hill

First Recieved on June 3, 2011

Last Updated on October 4, 2011

Sponsor: Michelle Hernandez, MD
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: University of North Carolina, Chapel Hill
Identifier: NCT01369017


The investigators want to see if healthy people who are given 2 doses of a medication called anakinra, which is used to treat moderate to severe rheumatoid arthritis, (RA) and then exposed to a form of air pollution, called Endotoxin, have less inflammation with the medication. Endotoxin is believed to be one of the causes of asthma attacks.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Accepts Healthy Volunteers

Inclusion Criteria: - healthy volunteers - age 18-50 years Exclusion Criteria: - asthma - pregnant women - smokers


  • Investigator: Michelle Hernandez, MD - Principal Investigator - UNC CH SOM


  • UNC Center for Environmental Medicine, Asthma and Lung Biology

    Chapel Hill, North Carolina 27599 United States

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.